Hims & Hers Empowers Patients with Direct-to-Consumer Lab Testing

As of November 13th, 2025, Hims & Hers, a leading virtual care platform with approximately 2.5 million subscribers, has announced a new partnership with Quest Diagnostics to offer direct-to-consumer laboratory testing services. This move aims to empower patients by providing them with greater access to comprehensive health data and personalized guidance.

Through this collaboration, Hims & Hers customers will now have the ability to choose from two blood testing plans. The base offering includes a single yearly blood draw that assesses 50 biomarkers for a $199 fee, while the advanced plan offers two yearly blood draws capturing over 120 biomarkers for $499. Regardless of the plan, patients' results will be reviewed by Hims & Hers' network of more than 2,000 medical providers, who will offer personalized recommendations and guidance on any necessary follow-up actions.

The demand for laboratory services has been steadily increasing, with the Centers for Disease Control and Prevention (CDC) reporting that approximately 14 billion lab tests are conducted in the United States each year, and 70% of medical decisions depend on them. Hims & Hers' chief medical officer, Dr. Pat Carroll, believes this new offering will align with the growing consumer preference for more proactive healthcare management, as patients seek to bypass the traditional medical system and take a more active role in interpreting their own health data.

By integrating lab testing with its existing treatment offerings, such as sexual health, hormone therapy, and weight management, Hims & Hers aims to provide a comprehensive and seamless healthcare experience for its customers. The company's strategy is to focus on areas where it can supplement, rather than replace, traditional healthcare providers, ensuring that patients receive the necessary guidance and support to make informed decisions about their well-being.